Register Login

GALAPAGOS NV (LKFT)

SymbolLKFT
NameGALAPAGOS NV
SectorHEALTH CARE
RegionEurope
IndustryPharmaceutical Preparations
AddressGEN DE WITTELAAN L11 A3, 2800 MECHELEN, C9 00000
Telephone3215342900
Fax—
Email—
Websitehttps://www.glpg.com
IncorporationUNDEFINED
Incorporated On1999
Employees—
Fiscal Year12/31
Public Since—
ExchangesNASDAQ;OTC
Auditor—
Audit StatusAUDITED
Reporting StatusU.S. Reporting: SEC Reporting
CIK0001421876
Description

Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The companys product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohns disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.

Additional info from NASDAQ:
Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The companys product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohns disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.

Additional info from OTC:
Galapagos is a midsized biotechnology company, with therapeutic programs based on proprietary disease modifying drug targets, and a focus on inflammation, orphan disease, and anti-infectives. Galapagos approach is to develop drugs that stop or reverse a disease state using novel targets that are identified through a patent protected target discovery platform. Galapagos also provides access to its target and drug discovery platform through its services division, BioFocus and Argenta, which offers a full suite of target-to-drug discovery products and services to pharmaceutical and biotech companies.

2026-08-12 20:01

Inkoop van eigen aandelen

Read more
2026-08-12 20:01

Acquisition of Own Shares

Read more
2026-08-10 20:01

Lakefront Biotherapeutics Reports Half-Year 2026 Financial Results and Provides Business Update

Read more
2026-08-10 20:01

Lakefront Biotherapeutics rapporteert halfjaarcijfers 2026 en geeft een update over de activiteiten

Read more
2026-08-04 20:01

Acquisition of Own Shares

Read more
2026-08-04 20:01

Inkoop van eigen aandelen

Read more
2026-07-28 20:01

Acquisition of Own Shares

Read more
2026-07-28 20:01

Inkoop van eigen aandelen

Read more
2026-07-21 20:01

Acquisition of Own Shares

Read more
2026-07-21 20:01

Inkoop van eigen aandelen

Read more
Product Name Type Development Stage Therapeutic Area Study Status Trial ID
Placebo, multiple ascending doses, oral suspension Other Phase PHASE1 Healthy COMPLETED NCT02179502
GLPG1690, multiple ascending doses, oral suspension Other Phase PHASE1 Healthy COMPLETED NCT02179502
Placebo single ascending doses Other Phase PHASE1 Healthy COMPLETED NCT02179502
GLPG1690 single ascending doses Other Phase PHASE1 Healthy COMPLETED NCT02179502
GLPG1837 1000 mg Other Phase PHASE1 Healthy COMPLETED NCT02562950
Midazolam Other Phase PHASE1 Healthy COMPLETED NCT02562950
GLPG1837 500 mg Other Phase PHASE1 Healthy COMPLETED NCT02562950
Placebo Oral Tablet Other Phase PHASE2 Psoriatic Arthritis COMPLETED NCT03101670
filgotinib Other Phase PHASE2 Psoriatic Arthritis COMPLETED NCT03101670
GLPG2737 Other Phase PHASE1 Cystic Fibrosis COMPLETED NCT03540524
GLPG2222 Other Phase PHASE1 Cystic Fibrosis COMPLETED NCT03540524
GLPG2451 dose regimen B Other Phase PHASE1 Cystic Fibrosis COMPLETED NCT03540524
GLPG2451 dose regimen A Other Phase PHASE1 Cystic Fibrosis COMPLETED NCT03540524
csDMARDs Other Phase PHASE3 Rheumatoid Arthritis COMPLETED NCT02873936
Placebo to match filgotinib Other Phase PHASE3 Rheumatoid Arthritis COMPLETED NCT02873936
Filgotinib Other Phase PHASE3 Rheumatoid Arthritis COMPLETED NCT02873936
Placebo Other Phase PHASE1 Plaque Psoriasis COMPLETED NCT04594928
GLPG3667 Other Phase PHASE1 Plaque Psoriasis COMPLETED NCT04594928
Placebo Other Phase PHASE2 Osteoarthritis COMPLETED NCT03595618
GLPG1972 Other Phase PHASE2 Osteoarthritis COMPLETED NCT03595618
Placebo Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT04577781
GLPG3970 Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT04577781
Filgotinib Other Phase PHASE1 Bioavailability COMPLETED NCT06043739
GLPG0259 Other Phase PHASE1 Healthy COMPLETED NCT01024517
GLPG0259 solution Other Phase PHASE1 Healthy COMPLETED NCT01024517
placebo Other Phase PHASE1 Healthy COMPLETED NCT01023321
GLPG0555 Other Phase PHASE1 Healthy COMPLETED NCT01023321
placebo Other Phase PHASE1 Healthy COMPLETED NCT01208753
GLPG0555 aqueous Other Phase PHASE1 Healthy COMPLETED NCT01208753
GLPG0555 Other Phase PHASE1 Healthy COMPLETED NCT01208753
GLPG0259 free base Other Phase PHASE1 Healthy COMPLETED NCT01322451
GLPG0259 fumarate Other Phase PHASE1 Healthy COMPLETED NCT01322451
GLPG0555 nanosuspension Other Phase PHASE1 Healthy COMPLETED NCT01278095
GLPG0555 solid dispersion Other Phase PHASE1 Healthy COMPLETED NCT01278095
placebo Other Phase PHASE1 Healthy COMPLETED NCT01179581
GLPG0634 Other Phase PHASE1 Healthy COMPLETED NCT01179581
Placebo (Part B) Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT01211249
GLPG0259 (Part B) Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT01211249
Placebo Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT01211249
GLPG0259 oral capsule Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT01211249
placebo Other Phase PHASE1 Healthy COMPLETED NCT01336244
GLPG0778 Other Phase PHASE1 Healthy COMPLETED NCT01336244
placebo Other Phase PHASE1 Healthy COMPLETED NCT01278108
GLPG0778 Other Phase PHASE1 Healthy COMPLETED NCT01278108
Placebo Other Phase PHASE1 Healthy COMPLETED NCT01397370
GLPG0492 Other Phase PHASE1 Healthy COMPLETED NCT01397370
Methotrexate Other Phase PHASE1 Healthy COMPLETED NCT00989703
GLPG0259 Other Phase PHASE1 Healthy COMPLETED NCT00989703
placebo Other Phase PHASE1 Healthy COMPLETED NCT00989703
Placebo Other Phase PHASE1 Healthy COMPLETED NCT01538420
GLPG0492 Other Phase PHASE1 Healthy COMPLETED NCT01538420
GLPG0974 Other Phase PHASE1 Healthy COMPLETED NCT01496937
GLPG0187 prodrug Drug Phase PHASE1 Healthy COMPLETED NCT01580644
Placebo Other Phase PHASE1 Healthy COMPLETED NCT01419990
GLPG0634 Other Phase PHASE1 Healthy COMPLETED NCT01419990
GLPG0634 Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT01384422
Placebo Other Phase PHASE1 Healthy COMPLETED NCT01721980
GLPG0974 Other Phase PHASE1 Healthy COMPLETED NCT01721980
GLPG0634 100mg capsule once a day for 10 days Other Phase PHASE1 Healthy COMPLETED NCT01665924
100 mg dose of [14C] GLPG0634 Other Phase PHASE1 Healthy COMPLETED NCT01820806
Midazolam Other Phase PHASE1 Healthy COMPLETED NCT01798979
GLPG0634 Other Phase PHASE1 Healthy COMPLETED NCT01798979
GLPG0187 Other Phase PHASE1 Solid Tumors COMPLETED NCT01313598
Placebo Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT01668641
GLPG0634 Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT01668641
200 mg GLPG0634 as tablets, fed Other Phase PHASE1 Healthy COMPLETED NCT01915667
200 mg GLPG0634 as tablets, fasted Other Phase PHASE1 Healthy COMPLETED NCT01915667
200 mg GLPG0634 as capsules, fasted Other Phase PHASE1 Healthy COMPLETED NCT01915667
Placebo, multiple ascending doses, oral suspension Other Phase PHASE1 Healthy COMPLETED NCT01887106
GLPG1205, multiple ascending doses, oral suspension Other Phase PHASE1 Healthy COMPLETED NCT01887106
Placebo single ascending doses, oral suspension Other Phase PHASE1 Healthy COMPLETED NCT01887106
GLPG1205 single ascending doses, oral suspension Other Phase PHASE1 Healthy COMPLETED NCT01887106
Placebo Other Phase PHASE2 Ulcerative Colitis COMPLETED NCT01829321
GLPG0974 Other Phase PHASE2 Ulcerative Colitis COMPLETED NCT01829321
100 mg GLPG1205 Other Phase PHASE1 Healthy COMPLETED NCT02143856
GLPG0634 Other Phase PHASE1 Renal Impairment COMPLETED NCT02084199
Placebo Other Phase PHASE1 Healthy COMPLETED NCT02162355
GLPG0634 200 mg Other Phase PHASE1 Healthy COMPLETED NCT02162355
GLPG0634 100 mg Other Phase PHASE1 Healthy COMPLETED NCT02162355
GLPG0634 50 mg Other Phase PHASE1 Healthy COMPLETED NCT02162355
Placebo multiple doses Other Phase PHASE1 Healthy COMPLETED NCT02325037
GLPG1837 multiple ascending doses Other Phase PHASE1 Healthy COMPLETED NCT02325037
Placebo single dose Other Phase PHASE1 Healthy COMPLETED NCT02325037
GLPG1837 single ascending doses Other Phase PHASE1 Healthy COMPLETED NCT02325037
500 mg GLPG1837 as oral tablet Other Phase PHASE1 Healthy COMPLETED NCT02562859
500 mg GLPG1837 as oral suspension Other Phase PHASE1 Healthy COMPLETED NCT02562859
Placebo Other Phase PHASE2 Ulcerative Colitis COMPLETED NCT02337608
GLPG1205 Other Phase PHASE2 Ulcerative Colitis COMPLETED NCT02337608
Cocktail of CYP450 substrates Other Phase PHASE1 Healthy COMPLETED NCT02623296
Placebo Other Phase PHASE1 Healthy COMPLETED NCT02623296
GLPG1205 Other Phase PHASE1 Healthy COMPLETED NCT02623296
Placebo Other Phase PHASE2 Crohn's Disease COMPLETED NCT02048618
GLPG0634 Other Phase PHASE2 Crohn's Disease COMPLETED NCT02048618
Placebo multiple doses Other Phase PHASE1 Healthy COMPLETED NCT02662452
GLPG2222 multiple doses Other Phase PHASE1 Healthy COMPLETED NCT02662452
Placebo single dose Other Phase PHASE1 Healthy COMPLETED NCT02662452
GLPG2222 single dose Other Phase PHASE1 Healthy COMPLETED NCT02662452
Placebo multiple doses Other Phase PHASE1 Healthy COMPLETED NCT02612246
GLPG1972 multiple ascending doses Other Phase PHASE1 Healthy COMPLETED NCT02612246
Placebo single dose Other Phase PHASE1 Healthy COMPLETED NCT02612246
GLPG1972 single ascending doses Other Phase PHASE1 Healthy COMPLETED NCT02612246
GLPG1972 600 mg oral tablet fed Other Phase PHASE1 Osteoarthritis COMPLETED NCT02851485
GLPG1972 600 mg oral tablet fasted Other Phase PHASE1 Osteoarthritis COMPLETED NCT02851485
GLPG1972 600 mg oral solution fasted Other Phase PHASE1 Osteoarthritis COMPLETED NCT02851485
Methylprednisolone Other Phase PHASE2 Acute Exacerbation of Remitting Relapsing Multiple Sclerosis TERMINATED NCT01039103
PEG-liposomal prednisolone sodium phosphate Other Phase PHASE2 Acute Exacerbation of Remitting Relapsing Multiple Sclerosis TERMINATED NCT01039103
GLPG1837 dose 2 Other Phase PHASE2 Cystic Fibrosis COMPLETED NCT02690519
GLPG1837 dose 1 Other Phase PHASE2 Cystic Fibrosis COMPLETED NCT02690519
GLPG1837 dose 3 Other Phase PHASE2 Cystic Fibrosis COMPLETED NCT02707562
GLPG1837 dose 2 Other Phase PHASE2 Cystic Fibrosis COMPLETED NCT02707562
GLPG1837 dose 1 Other Phase PHASE2 Cystic Fibrosis COMPLETED NCT02707562
GLPG1205 250 loading dose and 50mg q.d. maintenance dose Other Phase PHASE1 Healthy COMPLETED NCT03102567
Placebo oral capsule Other Phase PHASE1 Healthy COMPLETED NCT03102567
GLPG1205 50mg q.d. Other Phase PHASE1 Healthy COMPLETED NCT03102567
GLPG1972 Other Phase PHASE1 Healthy COMPLETED NCT03143725
GLPG1690 Other Phase PHASE1 Healthy COMPLETED NCT03143712
Placebo Other Phase PHASE1 Healthy COMPLETED NCT02788721
GLPG2451 single dose Other Phase PHASE1 Healthy COMPLETED NCT02788721
Combined Placebo multiple dose Other Phase PHASE1 Healthy COMPLETED NCT03214614
GLPG2451/GLPG2222 multiple dose Other Phase PHASE1 Healthy COMPLETED NCT03214614
Placebo multiple dose Other Phase PHASE1 Healthy COMPLETED NCT03214614
GLPG2451 multiple dose Other Phase PHASE1 Healthy COMPLETED NCT03214614
Placebo multiple intravenous administrations Other Phase PHASE1 Healthy COMPLETED NCT02739009
MOR106 multiple ascending doses, intravenous Other Phase PHASE1 Healthy COMPLETED NCT02739009
Placebo single ascending doses, intravenous Other Phase PHASE1 Healthy COMPLETED NCT02739009
MOR106 single ascending doses, intravenous Other Phase PHASE1 Healthy COMPLETED NCT02739009
Placebo Other Phase PHASE2 Cystic Fibrosis COMPLETED NCT03045523
GLPG2222 300 mg q.d. Other Phase PHASE2 Cystic Fibrosis COMPLETED NCT03045523
GLPG2222 150 mg q.d. Other Phase PHASE2 Cystic Fibrosis COMPLETED NCT03045523
Placebo Other Phase PHASE1 Osteoarthritis COMPLETED NCT03311009
GLPG1972 cohort 3 Other Phase PHASE1 Osteoarthritis COMPLETED NCT03311009
GLPG1972 cohort 2 Other Phase PHASE1 Osteoarthritis COMPLETED NCT03311009
GLPG1972 cohort 1 Other Phase PHASE1 Osteoarthritis COMPLETED NCT03311009
GLPG2737 multiple dose Other Phase PHASE1 Healthy COMPLETED NCT03410979
Placebo single dose Other Phase PHASE1 Healthy COMPLETED NCT03410979
GLPG2737 single dose Other Phase PHASE1 Healthy COMPLETED NCT03410979
GLPG2737 single dose Other Phase PHASE1 Cystic Fibrosis COMPLETED NCT03450720
GLPG3067/GLPG2222/GLPG2737 Placebo multiple dose Other Phase PHASE1 Healthy COMPLETED NCT03128606
GLPG3067/GLPG2222/GLPG2737 multiple dose Other Phase PHASE1 Healthy COMPLETED NCT03128606
GLPG3067/GLPG2222 Placebo multiple dose Other Phase PHASE1 Healthy COMPLETED NCT03128606
GLPG3067/GLPG2222 multiple dose Other Phase PHASE1 Healthy COMPLETED NCT03128606
GLPG3067 oral tablet Other Phase PHASE1 Healthy COMPLETED NCT03128606
GLPG3067 oral suspension Other Phase PHASE1 Healthy COMPLETED NCT03128606
Placebo multiple dose Other Phase PHASE1 Healthy COMPLETED NCT03128606
GLPG3067 multiple dose Other Phase PHASE1 Healthy COMPLETED NCT03128606
Placebo single dose Other Phase PHASE1 Healthy COMPLETED NCT03128606
GLPG3067 single dose Other Phase PHASE1 Healthy COMPLETED NCT03128606
Voriconazole Other Phase PHASE1 Healthy COMPLETED NCT03515382
Itraconazole Other Phase PHASE1 Healthy COMPLETED NCT03515382
GLPG1690 Other Phase PHASE1 Healthy COMPLETED NCT03515382
Placebo Other Phase PHASE2 Cystic Fibrosis COMPLETED NCT03474042
GLPG2737 Other Phase PHASE2 Cystic Fibrosis COMPLETED NCT03474042
GLPG3067 single dose Other Phase PHASE1 Cystic Fibrosis COMPLETED NCT03589313
Placebo Oral Tablet Other Phase PHASE2 Ankylosing Spondylitis COMPLETED NCT03117270
filgotinib Other Phase PHASE2 Ankylosing Spondylitis COMPLETED NCT03117270
GLPG2222 400 mg Other Phase PHASE2 Cystic Fibrosis COMPLETED NCT03119649
GLPG2222 200 mg Other Phase PHASE2 Cystic Fibrosis COMPLETED NCT03119649
Placebo Other Phase PHASE2 Cystic Fibrosis COMPLETED NCT03119649
GLPG2222 100 mg Other Phase PHASE2 Cystic Fibrosis COMPLETED NCT03119649
GLPG2222 50 mg Other Phase PHASE2 Cystic Fibrosis COMPLETED NCT03119649
[14C]-GLPG1690 capsules Other Phase PHASE1 Healthy COMPLETED NCT03787186
[14C]-GLPG1690 solution for infusion Other Phase PHASE1 Healthy COMPLETED NCT03787186
GLPG1690 film-coated tablets Other Phase PHASE1 Healthy COMPLETED NCT03787186
Placebo MAD Other Phase PHASE1 Healthy COMPLETED NCT03899909
GLPG3121 MAD Other Phase PHASE1 Healthy COMPLETED NCT03899909
Placebo SAD Other Phase PHASE1 Healthy COMPLETED NCT03899909
GLPG3121 SAD Other Phase PHASE1 Healthy COMPLETED NCT03899909
[14C]-GLPG1972 oral solution Other Phase PHASE1 Healthy COMPLETED NCT04136327
[14C]-GLPG1972 solution for infusion Other Phase PHASE1 Healthy COMPLETED NCT04136327
GLPG1972 film-coated tablets Other Phase PHASE1 Healthy COMPLETED NCT04136327
GLPG1972 - C Other Phase PHASE1 Healthy COMPLETED NCT04137341
GLPG1972 - B Other Phase PHASE1 Healthy COMPLETED NCT04137341
GLPG1972 - A Other Phase PHASE1 Healthy COMPLETED NCT04137341
Placebo Other Phase PHASE1 Healthy TERMINATED NCT03689829
MOR106 Other Phase PHASE1 Healthy TERMINATED NCT03689829
Placebo Other Phase PHASE2 Atopic Dermatitis TERMINATED NCT03568071
MOR 106 Other Phase PHASE2 Atopic Dermatitis TERMINATED NCT03568071
GLPG3312 FE MR Other Phase PHASE1 Healthy COMPLETED NCT03800472
GLPG3312 MR Other Phase PHASE1 Healthy COMPLETED NCT03800472
Placebo Other Phase PHASE1 Healthy COMPLETED NCT03800472
GLPG3312 IR Other Phase PHASE1 Healthy COMPLETED NCT03800472
Filgotinib placebo Other Phase PHASE2 Cutaneous Lupus Erythematosus COMPLETED NCT03134222
Lanraplenib placebo Other Phase PHASE2 Cutaneous Lupus Erythematosus COMPLETED NCT03134222
Filgotinib Other Phase PHASE2 Cutaneous Lupus Erythematosus COMPLETED NCT03134222
Lanraplenib Other Phase PHASE2 Cutaneous Lupus Erythematosus COMPLETED NCT03134222
Tirabrutinib placebo Other Phase PHASE2 Sjogren's Syndrome COMPLETED NCT03100942
Filgotinib placebo Other Phase PHASE2 Sjogren's Syndrome COMPLETED NCT03100942
Lanraplenib placebo Other Phase PHASE2 Sjogren's Syndrome COMPLETED NCT03100942
Tirabrutinib Other Phase PHASE2 Sjogren's Syndrome COMPLETED NCT03100942
Filgotinib Other Phase PHASE2 Sjogren's Syndrome COMPLETED NCT03100942
Lanraplenib Other Phase PHASE2 Sjogren's Syndrome COMPLETED NCT03100942
Placebo QD Other Phase PHASE2 Idiopathic Pulmonary Fibrosis COMPLETED NCT02738801
GLPG1690 600 mg QD Other Phase PHASE2 Idiopathic Pulmonary Fibrosis COMPLETED NCT02738801
Placebo Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT01888874
GLPG0634 Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT01888874
Placebo Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT01894516
GLPG0634 Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT01894516
Placebo Other Phase PHASE1 Healthy COMPLETED NCT04532567
GLPG1205 Other Phase PHASE1 Healthy COMPLETED NCT04532567
Placebo Other Phase PHASE2 Atopic Dermatitis TERMINATED NCT03864627
MOR106 Other Phase PHASE2 Atopic Dermatitis TERMINATED NCT03864627
Placebo to Match Filgotinib Other Phase PHASE3 Ankylosing Spondylitis WITHDRAWN NCT04483700
Filgotinib Other Phase PHASE3 Ankylosing Spondylitis WITHDRAWN NCT04483700
Placebo to Match Filgotinib Other Phase PHASE3 Ankylosing Spondylitis WITHDRAWN NCT04483687
Filgotinib Other Phase PHASE3 Ankylosing Spondylitis WITHDRAWN NCT04483687
Filgotinib Other Phase PHASE1 Rheumatoid Arthritis COMPLETED NCT03417778
Midazolam Other Phase PHASE1 Healthy COMPLETED NCT04736927
GLPG3667 Other Phase PHASE1 Healthy COMPLETED NCT04736927
GLPG3970 tablet Other Phase PHASE1 Healthy COMPLETED NCT04708184
GLPG3970 oral solution Other Phase PHASE1 Healthy COMPLETED NCT04708184
GLPG1205 capsules Other Phase PHASE1 Healthy COMPLETED NCT04704739
[14C]-GLPG1205 solution for infusion Other Phase PHASE1 Healthy COMPLETED NCT04704739
GLPG1205 film-coated tablets Other Phase PHASE1 Healthy COMPLETED NCT04704739
PTM filgotinib Other Phase PHASE3 Ulcerative Colitis COMPLETED NCT02914522
Filgotinib Other Phase PHASE3 Ulcerative Colitis COMPLETED NCT02914522
Placebo Other Phase PHASE2 Systemic Sclerosis COMPLETED NCT03798366
GLPG1690 Other Phase PHASE2 Systemic Sclerosis COMPLETED NCT03798366
GLPG4059 tablet Other Phase PHASE1 Healthy TERMINATED NCT04575818
Placebo Other Phase PHASE1 Healthy TERMINATED NCT04575818
GLPG4059 oral suspension Other Phase PHASE1 Healthy TERMINATED NCT04575818
Placebo to match MTX Other Phase PHASE3 Rheumatoid Arthritis COMPLETED NCT02886728
MTX Other Phase PHASE3 Rheumatoid Arthritis COMPLETED NCT02886728
Placebo to match filgotinib Other Phase PHASE3 Rheumatoid Arthritis COMPLETED NCT02886728
Filgotinib Other Phase PHASE3 Rheumatoid Arthritis COMPLETED NCT02886728
MTX Other Phase PHASE3 Rheumatoid Arthritis COMPLETED NCT02889796
Placebo to match adalimumab Other Phase PHASE3 Rheumatoid Arthritis COMPLETED NCT02889796
Adalimumab Other Phase PHASE3 Rheumatoid Arthritis COMPLETED NCT02889796
Placebo to match filgotinib Other Phase PHASE3 Rheumatoid Arthritis COMPLETED NCT02889796
Filgotinib Other Phase PHASE3 Rheumatoid Arthritis COMPLETED NCT02889796
[14]GLPG3970 oral solution Other Phase PHASE1 Healthy COMPLETED NCT04907149
[14C]GLPG3970 solution for infusion Other Phase PHASE1 Healthy COMPLETED NCT04907149
GLPG3970 film-coated tablet Other Phase PHASE1 Healthy COMPLETED NCT04907149
Placebo to match filgotinib Other Phase PHASE2 Small Bowel Crohn's Disease COMPLETED NCT03046056
Filgotinib Other Phase PHASE2 Small Bowel Crohn's Disease COMPLETED NCT03046056
Placebo Other Phase PHASE2 Idiopathic Pulmonary Fibrosis COMPLETED NCT03725852
GLPG1205 Other Phase PHASE2 Idiopathic Pulmonary Fibrosis COMPLETED NCT03725852
Placebo film-coated tablet Other Phase PHASE1 Systemic Lupus Erythematosus TERMINATED NCT04700267
GLPG3970 film-coated tablet Other Phase PHASE1 Systemic Lupus Erythematosus TERMINATED NCT04700267
Midazolam Other Phase PHASE1 Healthy COMPLETED NCT05030857
GLPG4716 Other Phase PHASE1 Healthy COMPLETED NCT05030857
Prednisone Other Phase PHASE2 Noninfectious Uveitis TERMINATED NCT03207815
Placebo to match filgotinib Other Phase PHASE2 Noninfectious Uveitis TERMINATED NCT03207815
Filgotinib Other Phase PHASE2 Noninfectious Uveitis TERMINATED NCT03207815
Placebo Other Phase PHASE1 Healthy COMPLETED NCT04653467
GLPG4399 capsules Other Phase PHASE1 Healthy COMPLETED NCT04653467
GLPG4399 oral suspension Other Phase PHASE1 Healthy COMPLETED NCT04653467
Placebo Other Phase PHASE1 Healthy COMPLETED NCT04976270
GLPG3667 Other Phase PHASE1 Healthy COMPLETED NCT04976270
Placebo to match filgotinib Other Phase PHASE3 Psoriatic Arthritis TERMINATED NCT04115839
Filgotinib Other Phase PHASE3 Psoriatic Arthritis TERMINATED NCT04115839
GLPG1690 Other Phase PHASE2 Systemic Sclerosis TERMINATED NCT03976648
Placebo to match filgotinib Other Phase PHASE2 Fistulizing Crohn's Disease COMPLETED NCT03077412
Filgotinib Other Phase PHASE2 Fistulizing Crohn's Disease COMPLETED NCT03077412
filgotinib Other Phase PHASE2 Psoriatic Arthritis TERMINATED NCT03320876
Placebo to match adalimumab Other Phase PHASE3 Psoriatic Arthritis TERMINATED NCT04115748
Placebo to match filgotinib Other Phase PHASE3 Psoriatic Arthritis TERMINATED NCT04115748
Adalimumab Other Phase PHASE3 Psoriatic Arthritis TERMINATED NCT04115748
Filgotinib Other Phase PHASE3 Psoriatic Arthritis TERMINATED NCT04115748
Filgotinib Other Phase PHASE1 Rheumatoid Arthritis COMPLETED NCT04608344
Rosuvastatin Other Phase PHASE1 Rheumatoid Arthritis COMPLETED NCT04608344
Pravastatin Other Phase PHASE1 Rheumatoid Arthritis COMPLETED NCT04608344
Atorvastatin Other Phase PHASE1 Rheumatoid Arthritis COMPLETED NCT04608344
[14C]-GLPG3667 capsule Other Phase PHASE1 Healthy COMPLETED NCT05335447
[14C]-GLPG3667 solution for infusion Other Phase PHASE1 Healthy COMPLETED NCT05335447
GLPG3667 capsule Other Phase PHASE1 Healthy COMPLETED NCT05335447
Placebo Other Phase PHASE3 Idiopathic Pulmonary Fibrosis TERMINATED NCT03733444
GLPG1690 Other Phase PHASE3 Idiopathic Pulmonary Fibrosis TERMINATED NCT03733444
Placebo Other Phase PHASE3 Idiopathic Pulmonary Fibrosis TERMINATED NCT03711162
GLPG1690 Other Phase PHASE3 Idiopathic Pulmonary Fibrosis TERMINATED NCT03711162
Adalimumab Other Phase PHASE4 Rheumatoid Arthritis UNKNOWN NCT05502731
Filgotinib Other Phase PHASE4 Rheumatoid Arthritis UNKNOWN NCT05502731
Intestinal ultrasound Other Preclinical Ulcerative Colitis UNKNOWN NCT05653791
JAK inhibitor treatment Drug Approved Colitis, Ulcerative RECRUITING NCT05456412
Placebo Other Phase PHASE2 Ulcerative Colitis COMPLETED NCT04577794
GLPG3970 Other Phase PHASE2 Ulcerative Colitis COMPLETED NCT04577794
Placebo Other Phase PHASE2 Primary Sjögren Syndrome TERMINATED NCT04700280
GLPG3970 Other Phase PHASE2 Primary Sjögren Syndrome TERMINATED NCT04700280
Placebo Other Phase PHASE3 Crohn's Disease COMPLETED NCT02914561
Filgotinib Other Phase PHASE3 Crohn's Disease COMPLETED NCT02914561
placebo Other Phase PHASE1 Healthy COMPLETED NCT01130818
GLPG0492 Other Phase PHASE1 Healthy COMPLETED NCT01130818
Standard of Care Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT03926195
Placebo Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT03926195
Filgotinib Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT03926195
Filgotinib Other Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT02065700
Placebo Other Phase PHASE3 Crohn's Disease TERMINATED NCT02914600
Filgotinib Other Phase PHASE3 Crohn's Disease TERMINATED NCT02914600
Placebo Other Phase PHASE2 Autosomal Dominant Polycystic Kidney Disease TERMINATED NCT04578548
GLPG2737 Other Phase PHASE2 Autosomal Dominant Polycystic Kidney Disease TERMINATED NCT04578548
Itraconazole Other Phase PHASE1 Healthy COMPLETED NCT05272683
GLPG3667 Other Phase PHASE1 Healthy COMPLETED NCT05272683
Nintedanib Other Phase PHASE1 Healthy COMPLETED NCT04971746
GLPG4716 Other Phase PHASE1 Healthy COMPLETED NCT04971746
Pirfenidone Other Phase PHASE1 Healthy COMPLETED NCT04971746
Placebo Other Phase PHASE1 Healthy COMPLETED NCT04856358
GLPG3121 Other Phase PHASE1 Healthy COMPLETED NCT04856358
GLPG3970 Other Phase PHASE1 Healthy COMPLETED NCT04720183
Sulfasalazine Other Phase PHASE1 Healthy COMPLETED NCT04720183
GLPG3970 capsule Other Phase PHASE1 Healthy COMPLETED NCT04106297
Placebo oral solution Other Phase PHASE1 Healthy COMPLETED NCT04106297
GLPG3970 oral solution Other Phase PHASE1 Healthy COMPLETED NCT04106297
GLPG3667 capsules Other Phase PHASE1 Healthy COMPLETED NCT04097938
Placebos Other Phase PHASE1 Healthy COMPLETED NCT04097938
GLPG3667 oral suspension Other Phase PHASE1 Healthy COMPLETED NCT04097938
Placebo Other Phase PHASE3 Ulcerative Colitis TERMINATED NCT05479058
Filgotinib Other Phase PHASE3 Ulcerative Colitis TERMINATED NCT05479058
Standard of Care Other Phase PHASE2 Inflammatory Bowel Disease TERMINATED NCT03201445
Placebo Other Phase PHASE2 Inflammatory Bowel Disease TERMINATED NCT03201445
Filgotinib Other Phase PHASE2 Inflammatory Bowel Disease TERMINATED NCT03201445
Synovial Biopsy Other Approved Rheumatoid Arthritis COMPLETED NCT07000890
50 patients will have a Free Choice between Filgotinib and anti TNF Other Phase PHASE4 Rheumatoid Arthritis RECRUITING NCT04985435
Anti-Tumor Necrosis Factor Alpha Drug (Product) Drug Phase PHASE4 Rheumatoid Arthritis RECRUITING NCT04985435
Filgotinib Other Phase PHASE4 Rheumatoid Arthritis RECRUITING NCT04985435
Placebo Other Phase PHASE2 Systemic Lupus Erythematosus ACTIVE_NOT_RECRUITING NCT05856448
GLPG3667 Other Phase PHASE2 Systemic Lupus Erythematosus ACTIVE_NOT_RECRUITING NCT05856448
Placebo Other Phase PHASE2 Dermatomyositis ACTIVE_NOT_RECRUITING NCT05695950
GLPG3667 Other Phase PHASE2 Dermatomyositis ACTIVE_NOT_RECRUITING NCT05695950
GLPG CAR T-cell therapy Drug Phase PHASE3 Hematological Malignancies RECRUITING NCT06652633
GLPG5101 Other Phase PHASE1 Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ACTIVE_NOT_RECRUITING NCT06561425
GLPG CAR T-cell therapy GENETIC Phase PHASE3 Hematological Malignancies RECRUITING NCT06652633
GLPG5101 GENETIC Phase PHASE1 Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ACTIVE_NOT_RECRUITING NCT06561425
JAK inhibitor treatment OTHER Approved Colitis, Ulcerative RECRUITING NCT05456412
[14C]-GLPG3667 capsule DRUG Phase PHASE1 Healthy COMPLETED NCT05335447
[14C]-GLPG3667 solution for infusion DRUG Phase PHASE1 Healthy COMPLETED NCT05335447
GLPG3667 capsule DRUG Phase PHASE1 Healthy COMPLETED NCT05335447
50 patients will have a Free Choice between Filgotinib and anti TNF BEHAVIORAL Phase PHASE4 Rheumatoid Arthritis RECRUITING NCT04985435
Anti-Tumor Necrosis Factor Alpha Drug (Product) DRUG Phase PHASE4 Rheumatoid Arthritis RECRUITING NCT04985435
Nintedanib DRUG Phase PHASE1 Healthy COMPLETED NCT04971746
GLPG4716 DRUG Phase PHASE1 Healthy COMPLETED NCT05030857
Pirfenidone DRUG Phase PHASE1 Healthy COMPLETED NCT04971746
[14]GLPG3970 oral solution DRUG Phase PHASE1 Healthy COMPLETED NCT04907149
[14C]GLPG3970 solution for infusion DRUG Phase PHASE1 Healthy COMPLETED NCT04907149
GLPG3121 DRUG Phase PHASE1 Healthy COMPLETED NCT04856358
Sulfasalazine DRUG Phase PHASE1 Healthy COMPLETED NCT04720183
GLPG3970 tablet DRUG Phase PHASE1 Healthy COMPLETED NCT04708184
GLPG1205 capsules DRUG Phase PHASE1 Healthy COMPLETED NCT04704739
[14C]-GLPG1205 solution for infusion DRUG Phase PHASE1 Healthy COMPLETED NCT04704739
GLPG1205 film-coated tablets DRUG Phase PHASE1 Healthy COMPLETED NCT04704739
Placebo film-coated tablet DRUG Phase PHASE1 Systemic Lupus Erythematosus TERMINATED NCT04700267
GLPG3970 film-coated tablet DRUG Phase PHASE1 Healthy COMPLETED NCT04907149
GLPG4399 capsules DRUG Phase PHASE1 Healthy COMPLETED NCT04653467
GLPG4399 oral suspension DRUG Phase PHASE1 Healthy COMPLETED NCT04653467
Rosuvastatin DRUG Phase PHASE1 Rheumatoid Arthritis COMPLETED NCT04608344
Pravastatin DRUG Phase PHASE1 Rheumatoid Arthritis COMPLETED NCT04608344
Atorvastatin DRUG Phase PHASE1 Rheumatoid Arthritis COMPLETED NCT04608344
GLPG3667 DRUG Phase PHASE2 Systemic Lupus Erythematosus ACTIVE_NOT_RECRUITING NCT05856448
GLPG3970 DRUG Phase PHASE1 Healthy COMPLETED NCT04720183
GLPG4059 tablet DRUG Phase PHASE1 Healthy TERMINATED NCT04575818
GLPG4059 oral suspension DRUG Phase PHASE1 Healthy TERMINATED NCT04575818
Placebo to Match Filgotinib DRUG Phase PHASE3 Ankylosing Spondylitis WITHDRAWN NCT04483700
GLPG1972 - C DRUG Phase PHASE1 Healthy COMPLETED NCT04137341
GLPG1972 - B DRUG Phase PHASE1 Healthy COMPLETED NCT04137341
GLPG1972 - A DRUG Phase PHASE1 Healthy COMPLETED NCT04137341
[14C]-GLPG1972 oral solution DRUG Phase PHASE1 Healthy COMPLETED NCT04136327
[14C]-GLPG1972 solution for infusion DRUG Phase PHASE1 Healthy COMPLETED NCT04136327
GLPG1972 film-coated tablets DRUG Phase PHASE1 Healthy COMPLETED NCT04136327
GLPG3970 capsule DRUG Phase PHASE1 Healthy COMPLETED NCT04106297
Placebo oral solution DRUG Phase PHASE1 Healthy COMPLETED NCT04106297
GLPG3970 oral solution DRUG Phase PHASE1 Healthy COMPLETED NCT04708184
GLPG3667 capsules DRUG Phase PHASE1 Healthy COMPLETED NCT04097938
Placebos DRUG Phase PHASE1 Healthy COMPLETED NCT04097938
GLPG3667 oral suspension DRUG Phase PHASE1 Healthy COMPLETED NCT04097938
Placebo MAD DRUG Phase PHASE1 Healthy COMPLETED NCT03899909
GLPG3121 MAD DRUG Phase PHASE1 Healthy COMPLETED NCT03899909
Placebo SAD DRUG Phase PHASE1 Healthy COMPLETED NCT03899909
GLPG3121 SAD DRUG Phase PHASE1 Healthy COMPLETED NCT03899909
GLPG3312 FE MR DRUG Phase PHASE1 Healthy COMPLETED NCT03800472
GLPG3312 MR DRUG Phase PHASE1 Healthy COMPLETED NCT03800472
GLPG3312 IR DRUG Phase PHASE1 Healthy COMPLETED NCT03800472
[14C]-GLPG1690 capsules DRUG Phase PHASE1 Healthy COMPLETED NCT03787186
[14C]-GLPG1690 solution for infusion DRUG Phase PHASE1 Healthy COMPLETED NCT03787186
GLPG1690 film-coated tablets DRUG Phase PHASE1 Healthy COMPLETED NCT03787186
MOR106 DRUG Phase PHASE2 Atopic Dermatitis TERMINATED NCT03864627
MOR 106 DRUG Phase PHASE2 Atopic Dermatitis TERMINATED NCT03568071
GLPG2222 DRUG Phase PHASE1 Cystic Fibrosis COMPLETED NCT03540524
GLPG2451 dose regimen B DRUG Phase PHASE1 Cystic Fibrosis COMPLETED NCT03540524
GLPG2451 dose regimen A DRUG Phase PHASE1 Cystic Fibrosis COMPLETED NCT03540524
Voriconazole DRUG Phase PHASE1 Healthy COMPLETED NCT03515382
Itraconazole DRUG Phase PHASE1 Healthy COMPLETED NCT05272683
GLPG2737 DRUG Phase PHASE2 Autosomal Dominant Polycystic Kidney Disease TERMINATED NCT04578548
GLPG2737 multiple dose DRUG Phase PHASE1 Healthy COMPLETED NCT03410979
GLPG2737 single dose DRUG Phase PHASE1 Cystic Fibrosis COMPLETED NCT03450720
GLPG1972 cohort 3 DRUG Phase PHASE1 Osteoarthritis COMPLETED NCT03311009
GLPG1972 cohort 2 DRUG Phase PHASE1 Osteoarthritis COMPLETED NCT03311009
GLPG1972 cohort 1 DRUG Phase PHASE1 Osteoarthritis COMPLETED NCT03311009
Combined Placebo multiple dose DRUG Phase PHASE1 Healthy COMPLETED NCT03214614
GLPG2451/GLPG2222 multiple dose DRUG Phase PHASE1 Healthy COMPLETED NCT03214614
GLPG2451 multiple dose DRUG Phase PHASE1 Healthy COMPLETED NCT03214614
Prednisone DRUG Phase PHASE2 Noninfectious Uveitis TERMINATED NCT03207815
Standard of Care DRUG Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT03926195
GLPG1972 DRUG Phase PHASE2 Osteoarthritis COMPLETED NCT03595618
GLPG1690 DRUG Phase PHASE2 Systemic Sclerosis TERMINATED NCT03976648
GLPG3067/GLPG2222/GLPG2737 Placebo multiple dose DRUG Phase PHASE1 Healthy COMPLETED NCT03128606
GLPG3067/GLPG2222/GLPG2737 multiple dose DRUG Phase PHASE1 Healthy COMPLETED NCT03128606
GLPG3067/GLPG2222 Placebo multiple dose DRUG Phase PHASE1 Healthy COMPLETED NCT03128606
GLPG3067/GLPG2222 multiple dose DRUG Phase PHASE1 Healthy COMPLETED NCT03128606
GLPG3067 oral tablet DRUG Phase PHASE1 Healthy COMPLETED NCT03128606
GLPG3067 oral suspension DRUG Phase PHASE1 Healthy COMPLETED NCT03128606
Placebo multiple dose DRUG Phase PHASE1 Healthy COMPLETED NCT03214614
GLPG3067 multiple dose DRUG Phase PHASE1 Healthy COMPLETED NCT03128606
GLPG3067 single dose DRUG Phase PHASE1 Cystic Fibrosis COMPLETED NCT03589313
GLPG2222 400 mg DRUG Phase PHASE2 Cystic Fibrosis COMPLETED NCT03119649
GLPG2222 200 mg DRUG Phase PHASE2 Cystic Fibrosis COMPLETED NCT03119649
GLPG2222 100 mg DRUG Phase PHASE2 Cystic Fibrosis COMPLETED NCT03119649
GLPG2222 50 mg DRUG Phase PHASE2 Cystic Fibrosis COMPLETED NCT03119649
GLPG1205 250 loading dose and 50mg q.d. maintenance dose DRUG Phase PHASE1 Healthy COMPLETED NCT03102567
Placebo oral capsule DRUG Phase PHASE1 Healthy COMPLETED NCT03102567
GLPG1205 50mg q.d. DRUG Phase PHASE1 Healthy COMPLETED NCT03102567
Placebo Oral Tablet DRUG Phase PHASE2 Ankylosing Spondylitis COMPLETED NCT03117270
filgotinib DRUG Phase PHASE2 Psoriatic Arthritis TERMINATED NCT03320876
Tirabrutinib placebo DRUG Phase PHASE2 Sjogren's Syndrome COMPLETED NCT03100942
Filgotinib placebo DRUG Phase PHASE2 Cutaneous Lupus Erythematosus COMPLETED NCT03134222
Lanraplenib placebo DRUG Phase PHASE2 Cutaneous Lupus Erythematosus COMPLETED NCT03134222
Tirabrutinib DRUG Phase PHASE2 Sjogren's Syndrome COMPLETED NCT03100942
Lanraplenib DRUG Phase PHASE2 Cutaneous Lupus Erythematosus COMPLETED NCT03134222
GLPG2222 300 mg q.d. DRUG Phase PHASE2 Cystic Fibrosis COMPLETED NCT03045523
GLPG2222 150 mg q.d. DRUG Phase PHASE2 Cystic Fibrosis COMPLETED NCT03045523
PTM filgotinib DRUG Phase PHASE3 Ulcerative Colitis COMPLETED NCT02914522
Placebo to match adalimumab DRUG Phase PHASE3 Psoriatic Arthritis TERMINATED NCT04115748
Adalimumab DRUG Phase PHASE4 Rheumatoid Arthritis NOT_YET_RECRUITING NCT05502731
Placebo to match MTX DRUG Phase PHASE3 Rheumatoid Arthritis COMPLETED NCT02886728
MTX DRUG Phase PHASE3 Rheumatoid Arthritis COMPLETED NCT02889796
csDMARDs DRUG Phase PHASE3 Rheumatoid Arthritis COMPLETED NCT02873936
Placebo to match filgotinib DRUG Phase PHASE3 Psoriatic Arthritis TERMINATED NCT04115839
GLPG1972 600 mg oral tablet fed DRUG Phase PHASE1 Osteoarthritis COMPLETED NCT02851485
GLPG1972 600 mg oral tablet fasted DRUG Phase PHASE1 Osteoarthritis COMPLETED NCT02851485
GLPG1972 600 mg oral solution fasted DRUG Phase PHASE1 Osteoarthritis COMPLETED NCT02851485
GLPG2451 single dose DRUG Phase PHASE1 Healthy COMPLETED NCT02788721
Placebo multiple intravenous administrations DRUG Phase PHASE1 Healthy COMPLETED NCT02739009
MOR106 multiple ascending doses, intravenous DRUG Phase PHASE1 Healthy COMPLETED NCT02739009
Placebo single ascending doses, intravenous DRUG Phase PHASE1 Healthy COMPLETED NCT02739009
MOR106 single ascending doses, intravenous DRUG Phase PHASE1 Healthy COMPLETED NCT02739009
Placebo QD DRUG Phase PHASE2 Idiopathic Pulmonary Fibrosis COMPLETED NCT02738801
GLPG1690 600 mg QD DRUG Phase PHASE2 Idiopathic Pulmonary Fibrosis COMPLETED NCT02738801
GLPG1837 dose 3 DRUG Phase PHASE2 Cystic Fibrosis COMPLETED NCT02707562
GLPG1837 dose 2 DRUG Phase PHASE2 Cystic Fibrosis COMPLETED NCT02707562
GLPG1837 dose 1 DRUG Phase PHASE2 Cystic Fibrosis COMPLETED NCT02707562
GLPG2222 multiple doses DRUG Phase PHASE1 Healthy COMPLETED NCT02662452
GLPG2222 single dose DRUG Phase PHASE1 Healthy COMPLETED NCT02662452
Cocktail of CYP450 substrates DRUG Phase PHASE1 Healthy COMPLETED NCT02623296
GLPG1972 multiple ascending doses DRUG Phase PHASE1 Healthy COMPLETED NCT02612246
GLPG1972 single ascending doses DRUG Phase PHASE1 Healthy COMPLETED NCT02612246
GLPG1837 1000 mg DRUG Phase PHASE1 Healthy COMPLETED NCT02562950
GLPG1837 500 mg DRUG Phase PHASE1 Healthy COMPLETED NCT02562950
500 mg GLPG1837 as oral tablet DRUG Phase PHASE1 Healthy COMPLETED NCT02562859
500 mg GLPG1837 as oral suspension DRUG Phase PHASE1 Healthy COMPLETED NCT02562859
GLPG1205 DRUG Phase PHASE1 Healthy COMPLETED NCT04532567
Placebo multiple doses DRUG Phase PHASE1 Healthy COMPLETED NCT02662452
GLPG1837 multiple ascending doses DRUG Phase PHASE1 Healthy COMPLETED NCT02325037
Placebo single dose DRUG Phase PHASE1 Healthy COMPLETED NCT03410979
GLPG1837 single ascending doses DRUG Phase PHASE1 Healthy COMPLETED NCT02325037
100 mg GLPG1205 DRUG Phase PHASE1 Healthy COMPLETED NCT02143856
GLPG0634 100mg capsule once a day for 10 days DRUG Phase PHASE1 Healthy COMPLETED NCT01665924
GLPG0555 nanosuspension DRUG Phase PHASE1 Healthy COMPLETED NCT01278095
GLPG0555 solid dispersion DRUG Phase PHASE1 Healthy COMPLETED NCT01278095
GLPG1690, multiple ascending doses, oral suspension DRUG Phase PHASE1 Healthy COMPLETED NCT02179502
Placebo single ascending doses DRUG Phase PHASE1 Healthy COMPLETED NCT02179502
GLPG1690 single ascending doses DRUG Phase PHASE1 Healthy COMPLETED NCT02179502
GLPG0634 200 mg DRUG Phase PHASE1 Healthy COMPLETED NCT02162355
GLPG0634 100 mg DRUG Phase PHASE1 Healthy COMPLETED NCT02162355
GLPG0634 50 mg DRUG Phase PHASE1 Healthy COMPLETED NCT02162355
Filgotinib DRUG Phase PHASE1 Bioavailability COMPLETED NCT06043739
200 mg GLPG0634 as tablets, fed DRUG Phase PHASE1 Healthy COMPLETED NCT01915667
200 mg GLPG0634 as tablets, fasted DRUG Phase PHASE1 Healthy COMPLETED NCT01915667
200 mg GLPG0634 as capsules, fasted DRUG Phase PHASE1 Healthy COMPLETED NCT01915667
Placebo, multiple ascending doses, oral suspension DRUG Phase PHASE1 Healthy COMPLETED NCT02179502
GLPG1205, multiple ascending doses, oral suspension DRUG Phase PHASE1 Healthy COMPLETED NCT01887106
Placebo single ascending doses, oral suspension DRUG Phase PHASE1 Healthy COMPLETED NCT01887106
GLPG1205 single ascending doses, oral suspension DRUG Phase PHASE1 Healthy COMPLETED NCT01887106
100 mg dose of [14C] GLPG0634 DRUG Phase PHASE1 Healthy COMPLETED NCT01820806
Midazolam DRUG Phase PHASE1 Healthy COMPLETED NCT05030857
GLPG0187 prodrug DRUG Phase PHASE1 Healthy COMPLETED NCT01580644
GLPG0974 DRUG Phase PHASE2 Ulcerative Colitis COMPLETED NCT01829321
GLPG0778 DRUG Phase PHASE1 Healthy COMPLETED NCT01336244
GLPG0259 free base DRUG Phase PHASE1 Healthy COMPLETED NCT01322451
GLPG0259 fumarate DRUG Phase PHASE1 Healthy COMPLETED NCT01322451
Placebo (Part B) DRUG Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT01211249
GLPG0259 (Part B) DRUG Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT01211249
GLPG0259 oral capsule DRUG Phase PHASE2 Rheumatoid Arthritis COMPLETED NCT01211249
GLPG0555 aqueous DRUG Phase PHASE1 Healthy COMPLETED NCT01208753
GLPG0634 DRUG Phase PHASE1 Renal Impairment COMPLETED NCT02084199
GLPG0492 DRUG Phase PHASE1 Healthy COMPLETED NCT01538420
Methylprednisolone DRUG Phase PHASE2 Acute Exacerbation of Remitting Relapsing Multiple Sclerosis TERMINATED NCT01039103
PEG-liposomal prednisolone sodium phosphate DRUG Phase PHASE2 Acute Exacerbation of Remitting Relapsing Multiple Sclerosis TERMINATED NCT01039103
GLPG0259 solution DRUG Phase PHASE1 Healthy COMPLETED NCT01024517
GLPG0555 DRUG Phase PHASE1 Healthy COMPLETED NCT01208753
Methotrexate DRUG Phase PHASE1 Healthy COMPLETED NCT00989703
Placebo DRUG Phase PHASE2 Systemic Lupus Erythematosus ACTIVE_NOT_RECRUITING NCT05856448
GLPG0187 DRUG Phase PHASE1 Solid Tumors COMPLETED NCT01313598
placebo DRUG Phase PHASE1 Healthy COMPLETED NCT01336244
GLPG0259 DRUG Phase PHASE1 Healthy COMPLETED NCT01024517
Total products: 491